Overview
Literature
FAQs

Resins for Antibody Purification

Monoclonal antibody (mAb) therapeutics are widely-used to treat ailments including cancer, rheumatoid arthritis, dementia and diabetes. Agarose-based chromatography resins are a vital technology for biopharmaceutical developers to obtain optimal purity in downstream mAb bioprocessing.

A Typical mAb Platform

The purification of commercially-available monoclonal antibodies (mAbs) on the market today is typically performed in three chromatography steps:

  1. Protein-A affinity resin is utilized as an initial antibody capture step. Praesto Protein A resins deliver exceptionally high purity (>99%) and yield in a single, efficient step.
  2. Sulphopropyl- (SP) functionalized cation exchange resin in 'bind and elute' mode is used to remove aggregates and HCP (Host Cell Proteins).
  3. Quarternary Amine (Q) functionalized anion exchange resin is used in 'flow-through' mode to remove trace contaminates and ensure sufficient viral clearance.

How do Protein and mAb Purification Resins Work?

Affinity chromatography is a method of separating proteins based on a highly specific, reversible interaction between an individual or group of proteins, and a suitable ligand (see selection table) attached to a chromatographic matrix.

Ion Exchange chromatography is used to separate molecules based on their net surface charge.

Anion exchange chromatography uses a positively charged ion exchange resin with an affinity for molecules having net negative surface charges.

Cation exchange chromatography uses a negatively charged ion exchange resin with an affinity for molecules having net positive surface charges.

The Praesto® range of agarose-based Protein A and Ion Exchange chromatography resins are industry-leading products, currently implemented into several hundred ongoing mAb screening projects and clinical trials globally. A key factor in this is our patented Jetting technology offering enhanced performance characteristics over commercially-available alternatives. 

Why is Jetting Different?

Most agarose-based resins on the market are produced using 'batch emulsification' technology. This was used to manufacture the very first agarose-based chromatography resins, around 60 years ago. Batch emulsification produces a relatively wide particle size distribution which also contains fine particles. These can increase back pressure and block column nets - not ideal for the increasing demands of modern downstream processing. 

Jetting, on the other hand, is a patented manufacturing process, which creates chromatographic resin beads with a uniform particle size distribution and no fine particles. This results in a multitude of benefits, from shorter lead times, to improved bead characteristics, to the possibility to create custom-designed bioprocessing resins specifically for our customers.

Jetting is being utilized by leading biopharmaceutical developers all over the world to streamline their mAb processes. Get in touch with our R&D and Applications scientists today, to see how Jetting technology can help you.

  • Performance

  • Reduced time in facility

  • Higher productivity

  • No net clogging or expensive packing failures

  • Precise lot-to-lot reproducibility

  • Custom particle sizes (available on request)

Monoclonal Antibody Purification Productos por Aplicación